Hyundai ADM Bio announced on the 14th that it will present preclinical results on the anticancer efficacy of OTX-M, an oral docetaxel and paclitaxel formulation, at the 'Biotech Showcase 2025' held in San Francisco, USA, from the 13th to the 15th.
OTX-M is an oral anticancer drug that improves the bioavailability of docetaxel and paclitaxel?representative chemotherapeutic agents previously administered only by injection due to low bioavailability?by more than 1600 times using an 'oral drug delivery platform technology.'
Preclinical results on anticancer efficacy confirmed that the 'metronomic chemotherapy' method, which involves taking small doses of OTX-M daily without breaks, minimizes side effects while maximizing anticancer effects.
Existing injectable anticancer drugs require hospital visits and treatment breaks, which reduce the continuity of cancer management. High-dose administration causes severe side effects, significantly lowering patients' quality of life and placing a heavy burden on the healthcare system.
Taking small daily doses of OTX-M without breaks can greatly reduce the toxicity and side effects caused by high-dose injections, improving patients' quality of life. By maintaining blood drug concentration, it maximizes the suppression of cancer cells, allowing cancer patients to manage their condition at home while maintaining daily life without hospital visits. It is expected to become a new standard in anticancer treatment.
Kim Taek-seong, CEO of Hyundai ADM, stated, "OTX-M will be a turning point that opens an era where cancer patients can manage cancer themselves like hypertension or diabetes." He explained, "Metronomic chemotherapy without breaks is a treatment method that reduces pain for cancer patients while maximizing therapeutic effects." He added, "We hope this research realized with oral anticancer drugs will suggest a new direction for cancer treatment."
The research results will be presented directly by Hyundai ADM CEO Kim Taek-seong at 10 a.m. local time on the 14th.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
